SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report: November 20, 2008
(Date of earliest event reported)
VASOMEDICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-18105 11-2871434
--------------------------------------------------------------------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
180 Linden Avenue, Westbury, New York 11590
------------------------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number including area code (516) 997-4600
--------------
Not applicable
--------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b)
[ ] Pre-commencement communications pursuant to Rule 13e-4c under the Exchange
Act (17 CFR 240.13e-4c)
Item 1.01 Entry into Material Definitive Agreement.
(a) On November 20, 2008, the Company entered into an Amendment to the
Distribution Agreement with Living Data Technology Corporation ("Living Data")
to expand the territory covered in the Distribution Agreement to provide for
exclusive distribution rights worldwide. In consideration for these rights, the
Company agreed to issue to Living Data 3,000,000 restricted shares of its common
stock.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
--------
10.1 Amendment to Distribution Agreement dated November 20, 2008
between Living Data Technology Corporation and Vasomedical, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
VASOMEDICAL, INC.
By: /s/ Jun Ma
-------------------------------------
Jun Ma
Chief Executive Officer and President
Dated: November 24, 2008